- Clinical Trials
- April 2024
- 80 Pages
Global
From €1900EUR$2,000USD£1,619GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1900EUR$2,000USD£1,619GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2375EUR$2,500USD£2,023GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1425EUR$1,500USD£1,214GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €1425EUR$1,500USD£1,214GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1425EUR$1,500USD£1,214GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1425EUR$1,500USD£1,214GBP
- Drug Pipelines
- April 2024
- 90 Pages
Global
From €1425EUR$1,500USD£1,214GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£1,012GBP
- Drug Pipelines
- January 2024
- 80 Pages
Global
From €1900EUR$2,000USD£1,619GBP
- Clinical Trials
- January 2024
- 280 Pages
Global
From €4750EUR$5,000USD£4,047GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1900EUR$2,000USD£1,619GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1425EUR$1,500USD£1,214GBP
- Clinical Trials
- April 2024
- 550 Pages
Global
From €4750EUR$5,000USD£4,047GBP
- Drug Pipelines
- April 2024
- 150 Pages
Global
From €2375EUR$2,500USD£2,023GBP
- Clinical Trials
- April 2024
- 170 Pages
Global
From €2375EUR$2,500USD£2,023GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£1,012GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£1,012GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£1,012GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1900EUR$2,000USD£1,619GBP
Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body.
PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more